Abstract PS1-12-17: Frequency and Prognostic Significance of ESR1 Mutations Post-CDK4/6 inhibitors in ER+/HER2− Metastatic Breast Cancer: Real-World Data from the GEICAM_RegistEM Study
Á. Guerrero-Zotano, Silvia Antolín, A. Tibau Martorell, J. Cruz-Jurado et autres
Abstract Background: Endocrine resistance in ER+/HER2- metastatic breast cancer is frequently mediated by ESR1 mutations. These mutations typically arise after prolonged endocrine therapy (ET) exposure in the metastatic setting, particularly with aromatase inhibitors (AI). This study evaluates the real-world evidence incidence and …
es (code pays fourni par la source)
1 citation
Clinical Cancer Research